
Weight loss drug maker Novo Nordisk has seen shares slump after warning over a sales plunge amid price cuts while a bumper profit haul from its Mounjaro rival Eli Lilly left it trailing behind.
Novo Nordisk – which makes Wegovy and Ozempic – forecast plunging sales in a surprise after-market announcement on Tuesday, which saw the Danish drugmaker’s shares plummet by nearly a fifth on Wednesday.